Dashboard/BEAM/BEAM-101/event

ReadoutTopline Readout

BEAM-101 BEACON Phase 1/2 SCD Update at ASH 2026

BEAM·BEAM-101·Sickle Cell Disease·

Phase 2

·NCT05456880

current best date

DEC

2026

MONTH7 months

Takeaway

Updated Phase 1/2 BEAM-101 data in sickle cell at ASH 2026 — Beam’s first base-editing therapy. Approved benchmark in same indication: CASGEVY. Watch: HbF % elevation, VOC reduction, conditioning-related safety.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~14%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAbase editing of HBG1/2 to reactivate fetal hemoglobin

BEAM-101 is an ex vivo base-editing therapy developed by Beam Therapeutics for sickle cell disease that uses an adenine base editor (ABE) to reactivate fetal hemoglobin in a patient's own blood stem cells. Unlike CRISPR/Cas9, which creates double-strand DNA breaks, base editing chemically converts a single DNA letter (A→G) at the HBG1/2 promoter without cutting the double helix — an approach designed to improve editing precision and reduce chromosomal rearrangements. Elevated fetal hemoglobin compensates for the defective adult sickle hemoglobin, preventing red cell sickling; BEAM-101 is in Phase 1/2 with data presented at hematology conferences.

Indication

Oncology - Heme

Sickle Cell Disease

MeSH · D000755

No primer in glossary yet.

Trial

active

NCT05456880 ↗

BEACON Phase 1/2 BEAM-101 in SCD

Glossary · what this readout is measuring

1 term detected in the takeaway

ASHconference
American Society of Hematology Annual Meeting
The major heme/onc meeting (~30,000 attendees). Early-December; key venue for blood cancer and rare hematology readouts.

Sector base rates · reference data

historical record · not prediction

of 1 historical Phase 2 readouts in Oncology - Heme: 1 positive, 0 mixed, 0 negative.

Positive

1/ 1

100%

Mixed

0/ 1

Negative

0/ 1

positive rate 100% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph2 readouts in Oncology - Heme have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

1/1

100% in record

Primary endpoint hit

100%

across 1 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

mosunetuzumab

RHHBY · r/r FL

Ph2 · Jun 2022positiveCR rate 60%conference

pirtobrutinib (BRUIN-321)

LLY · CLL

Ph3 · Dec 2024positivePFS HR 0.54PR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Oncology - Heme · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
reni-cel	EDIT	cell therapy	CRISPR/Cas12a HBG1/2 promoter edit	CONFERENCE · May 26
CASGEVYexagamglogene autotemcel	CRSP	cell therapy	CRISPR/Cas9 BCL11A enhancer edit	CONFERENCE · Dec 26
CB-010	CRBU	cell therapy	allogeneic CRISPR-edited anti-CD19 CAR-T	CONFERENCE · May 26
JAKAFIruxolitinib	INCY	small molecule	JAK1/JAK2 inhibitor	READOUT · Sep 26

Prior BEAM reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

+22.6%

Median 1M move

+31.3%

Positive outcomes

1/ 1

100%

Negative outcomes

0/ 1

Date	Headline	Outcome	1W	1M	6M
May 2025	BEAM-101 — Phase 2b Topline Met Primary Endpoint	positive	+22.6%	+31.3%	+31.6%

Historical BEAM stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 100%.

Disclosure trail

1 observation · sorted by confidence

Apr 22, 2026·8d agopinned · highest confidence
MED confPR
top claim
DEC2026
MONTH
“Beam plans to share an updated BEAM-101 dataset from the BEACON study at ASH 2026.”
conf 84%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.